

Име и презиме		Марина Костић	
Звање		Редовни професор	
Назив институције у којој наставник ради са пуним радним временом и од када		Факултет медицинских наука, Универзитет у Крагујевцу	2008.
Ужа научна односно уметничка област		Фармакологија и токсикологија	
Академска каријера			
	Година		Област
Избор у звање	2022.	Факултет медицинских наука, Универзитет у Крагујевцу	Фармакологија и токсикологија
Докторат	2011.	Медицински факултет, Универзитет у Крагујевцу	Медицина
Специјализација			
Магистратура			
Диплома	2006.	Медицински факултет, Универзитет у Крагујевцу	Медицина
Репрезентативне референце			
1.	Kostić M, Janković S, Desnica J, Lukić S, Mijailović S, Anđelković M, Stanojević Pirković M, Milovanović O, Spasić M, Vojinović T, Ružić Zečević D. Resource Use and Costs Related to Hematological Complications of Chemotherapy: Cost of Illness Study Based on Data from Balkan Country with Recent History of Socioeconomic Transition. Iran J Public Health. 2022;51(11):2573-2581.		
2.	Petković S, Milovanović O, Dragutinović N, Djurić S, Pavlović R, Ravić M, Kostić M, Petrović M, Tomović M, Djurić D. Analysis of the factors influencing consumer behavior in choosing of OTC medicines. Acta Poloniae Pharmaceutica - Drug Research. 2022;79(1):137-144.		
3.	Milosavljević MN, Kostić M, Milovanović J, Zarić RZ, Stojadinović M, Janković SM, Stefanović SM. Antimicrobial treatment of Erysipelatoclostridium ramosum invasive infections: a systematic review. Rev Inst Med Trop Sao Paulo. 2021;63:e30.		
4.	Božović B, Radoičić M, Janković S, Anđelković J, Kostić M. Pharmacoeconomic Aspects of Treating Hemorrhoidal Disease-Cost of Illness Study Based on Data from Balkan Country with Recent History of Social and Economic Transition. Iran J Public Health. 2021;50(6):1288-1290.		
5.	Kostić MJ, Živković Zarić RS, Janković SM. Risk factors for potential drug-drug interactions in a general neurology ward. Vojnosanit Pregl. 2021; doi: 10.2298/VSP190401105K.		
6.	Radoičić MJ, Božović BV, Ilić KD, Janković SM, Anđelković JZ, Kostić MJ. Pharmacoeconomic Aspects of Low Back Pain Treatment: Cost of Illness Study in the Republic of Serbia. Acta Med Port. 2019;32(4):272-278.		
7.	Živković Zarić RS, Pejčić AV, Janković SM, Kostić MJ, Milosavljević MN, Milosavljević MJ, Opančina VD. Antimicrobial treatment of Kocuria kristinae invasive infections: Systematic review. J Chemother. 2019;31(3):109-119.		
8.	Anđelković MV, Janković SM, Kostić MJ, Živković Zarić RS, Opančina VD, Živić MŽ, Milosavljević MJ, Pejčić AV. Antimicrobial treatment of Stenotrophomonas maltophilia invasive infections: Systematic review. J Chemother. 2019;31(6):297-306.		
9.	Kostić M, Milosavljević MN, Stefanović S, Ranković G, Janković SM. Cost-utility of tafenoquine vs. primaquine for the radical cure (prevention of relapse) of Plasmodium vivax malaria. J Chemother. 2020;32(1):21-29.		
10.	Milovanović JR, Janković SM, Milovanović D, Ružić Zečević D, Folić M, Kostić M, Ranković G, Stefanović S. Contemporary surgical management of drug-resistant focal epilepsy. Expert Rev Neurother. 2020;20(1):23-40.		
11.	Jović Z, Janković SM, Ružić Zečević D, Milovanović D, Stefanović S, Folić M, Milovanović J, Kostić M. Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis. Eur J Drug Metab Pharmacokinet. 2018; doi: 10.1007/s13318-018-0513-7.		
12.	Milosavljević MN, Janković SM, Pejčić AV, Milovanović JR, Opančina VD, Kostić MJ. Reslizumab versus placebo for poorly controlled, severe eosinophilic asthma: meta-analysis. Vojnosanit Pregl. 2018;75(9):884-96.		
13.	Janković SM, Tešić D, Anđelković J, Kostić M. Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review. Expert Rev Pharmacoecon Outcomes Res 2018; 18(5):461-474.		
14.	Jankovic SM, Dajic M, Jacovic S, Markovic S, Papic T, Petrusic T, Radojkovic M, Rankovic A, Tanaskovic M, Vasic M, Vukicevic D, Zarić RZ, Kostic M. Measuring Patients' Knowledge About Adverse Effects of Angiotensin-Converting Enzyme Inhibitors. J Patient Saf 2016 doi: 10.1097/PTS.0000000000000244		
15.	Milovanović JR, Janković SM, Pejčić A, Milosavljević M, Opančina V, Radonjić V, Protrka Z, Kostić M. Evaluation of brivaracetam: a new drug to treat epilepsy. Expert Opin Pharmacother 2017; 18(13):1381-1389.		
16.	Kostić M, Djaković L, Šujić R, Godman B, Janković SM. Inflammatory Bowel Diseases (Crohn's Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications. Appl Health Econ Health Policy 2017;15(1):85-93.		
17.	Guzvic V, Catic T, Kostic M. Health Technology Assessment in Central-Eastern and South Europe Countries: Bosnia and Herzegovina. Int J Technol Assess Health Care. 2017;33(3):390-395.		
18.	Dabanović V, Kostić M, Janković S. Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia—The Markov model based on data from Montenegro. Vojnosanit Pregl 2016; 73(1):26-33		
19.	Jankovic SM, Stojadinovic D, Stojadinovic M, Jankovic SV, Djuric JM, Stojic I, Kostic M. Angiotensin Receptor Blocker Losartan Inhibits Spontaneous Motility of Isolated Human Ureter. Eur J Drug Metab Pharmacokinet 2016;41(6):835-838.		
20.	Djokovic J, Milovanovic B, Milovanovic JR, Milovanovic O, Stojic I, Mrvic S, Kostic M, Stefanovic S, Jankovic SM. Translation of the Medical Fear Survey to Serbian: psychometric properties. Hippokratia 2016; 20 (1):44-9.		
21.	Sazdanovic P, Jankovic SM, Kostic M, Dimitrijevic A, Stefanovic S. Pharmacokinetics of linezolid in critically ill patients. Expert Opin Drug Metab Toxicol 2016;12(6):595-600.		
22.	Janković SM, Kostić M. Cost-Effectiveness of Introducing Point-of-Care Test for Detection of Level of Glycogen Phosphorylase in Early Diagnostic Algorithm of Acute Coronary Syndrome. Value Health Reg Issues. 2016;10:79-84.		
23.	Tesić D, Kostić M, Paunović D, Janković SM. Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia. Kardiol Pol. 2015;73(4):287-95.		
24.	MT. Tomović, SM. Cupara, MT. Popović-Milenković, BT. Ljuić, MJ. Kostić, SM. Janković. Antioxidant and anti-inflammatory activity of Potentilla reptans L. Acta Poloniae Pharmaceutica - Drug Research 2015; 72(1):137-145.		
25.	Kostić M, Jovanović S, Tomović M, Popović Milenković M, Janković SM. Cost- effectiveness analysis of tocilizumab in combination with metotrexate for rheumatoid arthritis: a Markov model based on data from a Balkan country in socio economic transition. Vojnosanit Pregl 2014; 71(2): 144–148.		
26.	Djordjevic N, Bogojevic J, and Kostic M. Alcohol consumption among adolescents in Kraljevo, Serbia. Cent Eur J Med 2011; 6(3): 363-371		
27.	Jankovic SM, Kostic M, Radosavljevic M, Tesic D, Stefanovic-Stoimenov N, Stevanovic I, Rakovic S, Aleksic J, Folic M, Aleksic A, Mihajlovic I, Biorac N, Borlja J. and Vuckovic R. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data from a Balkan country in socio-economic transition. Vojnosanit Pregl 2009; 66(7):556-562		
28.	Jankovic SM, Aleksic J, Rakovic S, Aleksic A, Stevanovic I, Stefanovic-Stoimenov N, Radosavljevic M, Kostic M, Tesic D, Petrovic B. Nonsteroidal antiinflammatory drugs and risk of gastrointestinal bleeding among patients on hemodialysis. J Nephrol 2009; 22(4):502-507.		
29.	Jankovic SM, Kostic M, Radosavljevic M, Jovanovic S. Costs of Rheumatoid Arthritis in a Balkan Country (Serbia). E Eur Polit Soc 2009; 23(1):135-138		
30.	Janković SM, Kostić MJ, Milovanović JR. Method for Adjusting Results of Pharmacoeconomic Studies from Country to Country Using Bayesian Statistics. Hospital Pharmacology. 2021;8(1):998-1003.		

31.	Kostić MJ, Vučković ŽM, Desnica JV, Knežević SM, Knežević J, Janković SM. Pharmacoeconomic aspects of treating childhood pneumonia – cost of illness study based on data from Serbia. Ser J Exp Clin Res. 2021; doi: 10.2478/sjecr-2021-0040.		
32.	Desnica J, Vujović S, Stevanović M, Vasović M, Stanišić D, Ognjanović I, Rosić G, Janković S, Jovičić N, Kostić M. Gingival enlargement caused by calcium channel blockers. Ser J Exp Clin Res. 2021; doi: 10.2478/sjecr-20210061.		
33.	Kostić M. Rheumatoid arthritis: a novel approach in diagnosis and treatment. Serb J Exp Clin Res. 2018. doi: 10.1515/sjecr-2016-0068.		
34.	Kostić M. Cost effectiveness analysis of etanercept in combination with methotrexate for rheumatoid arthritis – Markov model based on data from Serbia. Serb J Exp Clin Res. 2017;18(4):343-7.		
35.	Praznik I, Spasić M, Radosavljević I, Stojanović B, Čanović D, Radovanović D, Savović Z, Vojinović R, Babić Ž, Đonović N, Luković T, Lazarević P, Đorđević N, Kostić I, Jelić I, Petrović J, Stojanović S, Jurišević M, Grubor I, Nikolić Lj, Vučićević K, Artinović V, Milojević A, Kostić M, Stefanović S, Janković S. Analysis of Treatment-Related Factors Affecting Mortality in Patients with Severe Necrotizing Acute Pancreatitis. Acta Facultatis medicae Naissensis. 2016;33(3):173–185.		
36.	Marković V, Kostić M, Iličković I, Janković SM. Cost-Effectiveness Comparison of Fidaxomicin and Vancomycin for Treatment of Clostridium difficile Infection: A Markov Model Based on Data from a South West Balkan Country in Socioeconomic Transition. Value Health Reg Issues. 2014;4:87-94.		
Збирни подаци научне, односно уметничке и стручне активности наставника			
Укупан број цитата	Science Citation Index, Web of Science		
	Scopus		
Укупан број радова са SCI или (SSCI) листе у последњих 10 година	25		
Тренутно учешће на пројектима	1	Домаћи	1
		Међународни	
Усавршавања			
Други релевантни подаци	Чланство: ISPOR		